Table 1.
Cell line | IC50value (nM) | IC50standard error | Breast cancer subtype | ER status | HER2 status |
---|---|---|---|---|---|
MDA-MB-175 | 4 | 0.4 | Luminal | Positive | Normal |
ZR-75-30 | 5 | 0.5 | Luminal | Positive | Amplified |
CAMA-1 | 8 | 0.4 | Luminal | Positive | Normal |
MDA-MB-134 | 13 | 1.3 | Luminal | Positive | Normal |
HCC-202 | 21 | 2.3 | Luminal | Positive | Amplified |
UACC-893 | 24 | 1.6 | Luminal | Positive | Amplified |
EFM-19 | 27 | 12.3 | Luminal | Positive | Normal |
SUM-190 | 28 | 1.3 | Luminal | Positive | Amplified |
EFM-192A | 42 | 21.2 | Luminal | Positive | Amplified |
MDA-MB-361 | 44 | 4.1 | Luminal | Positive | Amplified |
HCC-1500 | 45 | 22.6 | Luminal | Positive | Normal |
HCC-1419 | 51 | 3.7 | Luminal | Positive | Amplified |
HCC-38 | 64 | 14.8 | Basal | Negative | Normal |
MDA-MB-415 | 64 | 6.6 | Luminal | Positive | Normal |
MCF-10A | 92 | 0.1 | n/a | Negative | Immortalized |
UACC-812 | 96 | 4.6 | Luminal | Positive | Amplified |
HCC-2218 | 100 | 17.0 | Luminal | Positive | Amplified |
ZR-75-1 | 110 | 54.1 | Luminal | Positive | Normal |
MDA-MB-453 | 115 | 1.4 | Luminal | Negative | Amplified |
184A1 | 118 | 2.0 | n/a | Negative | Immortalized |
T47-D | 127 | 15.0 | Luminal | Positive | Normal |
MCF-7 | 148 | 25.7 | Luminal | Positive | Normal |
BT-20 | 177 | 3.1 | Basal | Negative | Normal |
MDA-MB-435 | 201 | 7.5 | Post-EMT | Negative | Normal |
BT-474 | 240 | 64.5 | Luminal | Positive | Amplified |
SK-BR-3 | 300 | 83.0 | Luminal | Negative | Amplified |
KPL-1 | 327 | 64.3 | Luminal | Positive | Normal |
HCC-1143 | 359 | 99.7 | Basal | Negative | Normal |
MDA-MB-231 | 432 | 16.1 | Post-EMT | Negative | Normal |
HCC-1395 | 472 | 39.8 | Post-EMT | Negative | Normal |
SUM-225 | 503 | 55.7 | Luminal | Negative | Amplified |
Hs578t | 524 | 12.3 | Post-EMT | Negative | Normal |
184B5 | 538 | 41.1 | n/a | Negative | Immortalized |
UACC-732 | 744 | 14.9 | Luminal | Positive | Amplified |
CAL-51 | 905 | 0.0 | Post-EMT | Negative | Normal |
BT-549 | 1,000 | n/a | Post-EMT | Negative | Normal |
COLO-824 | 1,000 | n/a | Basal | Negative | Normal |
DU4475 | 1,000 | n/a | Basal | Negative | Normal |
HCC-1187 | 1,000 | n/a | Basal | Negative | Normal |
HCC-1569 | 1,000 | n/a | Post-EMT | Negative | Amplified |
HCC-1806 | 1,000 | n/a | Basal | Negative | Normal |
HCC-1937 | 1,000 | n/a | Post-EMT | Negative | Normal |
HCC-1954 | 1,000 | n/a | Basal | Negative | Amplified |
HCC-70 | 1,000 | n/a | Basal | Negative | Normal |
MDA-MB-436 | 1,000 | n/a | Post-EMT | Negative | Normal |
MDA-MB-157 | 1,000 | n/a | Post-EMT | Negative | Normal |
MDA-MB-468 | 1,000 | n/a | Basal | Negative | Normal |
Included are molecular subtype and estrogen receptor (ER) and HER2 status. Cell lines representing the luminal ER-positive subtype were most sensitive to the growth inhibition effects of PD 0332991. n/a, not applicable; Post-EMT, cell lines classified as representing breast cancers that had undergone an epithelial-to-mesenchymal transition.